Aktienanalyse zu Collegium Pharmaceutical Inc (COLL)COLLCollegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. Its portfolio also includes AZSTARYS (serdexmethylphenidate and dexmethylphenidate), a central nervous system (CNS) stimulant prescription medicine used for the treatment of ADHD in people six years of age and older. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Collegium Pharmaceutical Inc is not a good buy right now due to significant recent declines and negative sentiment. The current price is $25.35, which is down 44.32% year-to-date, and the RSI is at a very low 19.302, indicating oversold conditions but also a lack of buying momentum. The company's recent Q2 earnings showed a revenue of $199.9 million, which missed expectations of $201.2 million, highlighting ongoing challenges in the pain business. Additionally, insider selling has increased by 145.95% over the last month, suggesting a lack of confidence from those closest to the company. The main risk is the company's declining performance in its pain franchise, which has faced pricing pressures, contributing to a negative outlook.

7 analysts cover COLL: 7 rate it Buy, 0 Hold and 0 Sell. The average price target is 56.75.